| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'uspio' found in 0 term [] and 14 definitions []
| previous 6 - 10 (of 14) nextResult Pages : [1 2 3] | | | | Searchterm 'uspio' was also found in the following service: | | | | |
| | |
| |
|
Short name: Ami 227, generic name: Ferumoxtran, (USPIO)
Ferumoxtran is a substance of the class of ultrasmall superparamagnetic iron oxide used as a lymph node specific contrast agent for MRI.
See also Combidex®, Sinerem® and Ultrasmall Superparamagnetic Iron Oxide.
Partner(s): Cytogen Corporation, National Cancer Institute.
An approvable letter was received from the U.S. Food and Drug Administration for Combidex in June 2000. Advanced Magnetics, Inc. has submitted a complete response to the approvable letter received from the U.S. Food and Drug Administration, which was accepted by the FDA and assigned a user fee goal date of March 30, 2005.
In Europe, a Dossier (the European equivalent of a NDA) was submitted by Advanced Magnetics' European partner, Guerbet SA, to the European Medicines Evaluations Agency in December 1999.
( Sinerem® is the brand name for this USPIO in Europe manufactured by Guerbet, Combidex® by Advanced Magnetics for the U.S. market)
Advanced Magnetics, Inc. changed its name in July 2007 to AMAG Pharmaceuticals Inc. | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'Superparamagnetic Contrast Agents' (12).
| | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'Blood Pool Agents' (16).
| | | • View the NEWS results for 'Blood Pool Agents' (1).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | Searchterm 'uspio' was also found in the following service: | | | | |
| | |
| |
|
A bolus is a rapid infusion of high dose contrast agent. Dynamic and accumulation phase imaging can be performed after bolus injection. Since the transit time of the bolus through the tissue is only a few seconds, high temporal resolution imaging can be required to obtain sequential images during the wash in and wash out of the contrast material and, therefore, resolve the first pass of the tracer.
For the same injected dose of contrast agent the injection rate (and, consequently, the total injected volume) modifies the bolus peak profile. Increasing the injection rate produces a sharpening of the peak
(Cmax increase, Tmax decrease, peak length decrease). At a
low injection rate, the first pass presents a plateau form.
Substantial changes in the gadolinium concentrations during signal acquisition induce artifacts. Furthermore, the haemodynamic
parameters ( cardiac output, blood pressure) influence
the bolus profile.
The characteristics of gadolinium agents are favorable in the early bolus
phase, whereas the advantages of large complexes (e.g. blood pool agents) and ultrasmall superparamagnetic iron oxide ( USPIO) are most evident in the distribution phase. | | | | | | • View the DATABASE results for 'Bolus Injection' (9).
| | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
Drug Information and Specification
T2, Predominantly negative enhancement
PHARMACOKINETIC
Intravascular
CONCENTRATION
29.8 mg Fe/mL
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
Cardiovascular
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
| | | | • View the DATABASE results for 'Clariscan™' (6).
| | | | Further Reading: | News & More:
|
|
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |